All News
Full results from the Phase III trial of Novavax’s proposed COVID-19 vaccine demonstrated the drug’s efficacy in preventing mild, moderate, and severe illness.
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
Another flu season, another less than effective flu vaccine. The shape-shifting virus has mutated already and this year’s flu vaccine is a poor match to fight it.
Biogen and Eisai reported that the Committee for Medicinal Products for Human Use of the European Medicines Agency had decided not to recommend the drug for its MAA.
Biopharma companies are eying the establishment of new facilities across the globe that will bolster their manufacturing strategies. BioSpace rounds up some of the latest announcements.
In addition to showcasing data from their in-progress Phase I clinical trial, Kymera Therapeutics also announced their newest development program and outlined the company’s 5-year plan in their very first R&D Day.
With the holidays around the corner and people expected to gather, public health officials have expressed concerns over a possible increase in COVID-19 cases, particularly with the highly infectious Omicron variant on the rise.
U.S. District Judge Colleen McMahon rejected a bankruptcy plan that shielded the Sackler family from potential lawsuits related to the opioid crisis.
In a unanimous vote made by U.S. health officials, the advisers decided the safer Pfizer and Moderna vaccines should be given as boosters.
BeiGene and other China-based pharma companies have been nervously watching the Biden administration and its response to some companies in that region that have allegedly been involved with the Chinese military’s weapons programs and human rights violations.
The avalanche of news released every day about all three - or various combinations thereof - can be overwhelming. So, BioSpace has put together a chart for easy comparative reference.
It is also a milestone for the immunoglobulin A nephropathy (IgAN) community, as TARPEYO becomes the first and only FDA-approved treatment to reduce proteinuria in this condition.
As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers.
The new funding will allow the biotech company to advance its programs and accelerate the development of life-saving treatments for neurodegenerative diseases.
The agreement between the two companies includes a lead, potential first-in-class preclinical candidate, and research collaboration to jointly develop the additional novel candidates.
A recent study estimates that in the U.S. alone the vaccines saved 1.1 million lives and prevented 10.3 million hospitalizations. For that and more COVID-19 news, continue reading.
Arc begins its mission with $650 million in donations from donors. This funding will sustain the scientists and their researchers over renewable eight-year terms.
A recent study identified a hormone that may drive both type 1 and type 2 diabetes. For that and more research stories, read on.
Deaths from drug overdoses have been on an upward trajectory for years, but have experienced a notable increase since the early days of the COVID-19 pandemic.
Biogen and Eisai released an update on the Phase IV post-marketing confirmatory study and plan to submit the final protocol to the FDA in March 2022 and launch patient screening in May 2022.